Refractory lupus erythematosus tumidus responsive to tildrakizumab

Dermatol Ther. 2019 Sep;32(5):e13070. doi: 10.1111/dth.13070. Epub 2019 Sep 3.

Authors

Fathima F Ismail¹, Rodney D Sinclair^{1

2}, Joel Pinczewski³

Affiliations

¹ Sinclair Dermatology, East Melbourne, Victoria, Australia.
² University of Melbourne, Parkville, Victoria, Australia.
³ Dorevitch Pathology, Heidelberg, Victoria, Australia.

PMID: 31442369
DOI: 10.1111/dth.13070

No abstract available

Publication types

Case Reports
Letter
Review

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Biopsy, Needle
Drug Administration Schedule
Facial Dermatoses / diagnosis
Facial Dermatoses / drug therapy
Follow-Up Studies
Humans
Immunohistochemistry
Immunosuppressive Agents / therapeutic use
Injections, Intralesional
Lupus Erythematosus, Discoid / diagnosis
Lupus Erythematosus, Discoid / drug therapy*
Male
Quality of Life
Treatment Failure
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
tildrakizumab